# Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension

> **NCT00420342** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 92 (actual)

## Conditions studied

- Postmenopause
- Hypertension
- Pre-Hypertension

## Interventions

- **DRUG:** Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)
- **DRUG:** Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)
- **DRUG:** SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)

## Key facts

- **NCT ID:** NCT00420342
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2015-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00420342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00420342, "Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00420342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*